KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) EBITDA Margin (2016 - 2025)

Pfizer (PFE) has disclosed EBITDA Margin for 17 consecutive years, with 59.58% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 7859.0% to 59.58% in Q4 2025 year-over-year; TTM through Dec 2025 was 33.86%, a 29425.0% decrease, with the full-year FY2025 number at 33.86%, up 48014.0% from a year prior.
  • EBITDA Margin was 59.58% for Q4 2025 at Pfizer, up from 343.39% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 138.17% in Q4 2024 to a low of 2461.54% in Q3 2024.
  • A 5-year average of 194.18% and a median of 34.68% in 2021 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -244727bps in 2024, then surged 211815bps in 2025.
  • Pfizer's EBITDA Margin stood at 15.28% in 2021, then surged by 197bps to 45.45% in 2022, then tumbled by -1002bps to 410.13% in 2023, then soared by 134bps to 138.17% in 2024, then crashed by -57bps to 59.58% in 2025.
  • Per Business Quant, the three most recent readings for PFE's EBITDA Margin are 59.58% (Q4 2025), 343.39% (Q3 2025), and 34.86% (Q2 2025).